Antimelanoma immunotherapy: Clinical and preclinical applications of IL-12 family members

Immunotherapy

Volumn 2, Issue 5, 2010, Pages 697-709

  Nagai, Hiroshi ^a   Oniki, Shuntaro ^a   Fujiwara, Susumu ^a   Yoshimoto, Takayuki ^b   Nishigori, Chikako ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

adverse effect; antiangiogenesis; antiproliferation; IFN ; IL 12; IL 23; IL 27; immunotherapy; melanoma

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 27; TUMOR VACCINE;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; CARCINOGENESIS; HUMAN; IMMUNOTHERAPY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-12; INTERLEUKIN-23; INTERLEUKINS; MELANOMA;

EID: 77957604763     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.46     Document Type: Review

References (59)

1. Thompson JF, Scolyer RA, Kefford RF: Cutaneous melanoma. Lancet 365(9640), 687-701 (2005).
2. Rosenberg SA, Packard BS, Aebersold PM et al.: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319(25), 1676-1680 (1988). □ First report to demonstrate the regression of cancer using tumor-infiltrating lymphocytes for the immunotherapy of metastatic melanoma patients.
3. Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S: Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am. J. Pathol. 154(3), 745-754 (1999).
4. Chiou SH, Sheu BC, Chang WC et al.: Current concepts of tumor-infiltrating lymphocytes in human malignancies. J. Reprod. Immunol. 67(1-2), 35-50 (2005).
5. Hodi FS: Well-defined melanoma antigens as progression markers for melanoma: insights into differential expression and host response based on stage. Clin. Cancer Res. 12 (3 Pt 1), 673-678 (2006).
6. Markel G, Seidman R, Stern N et al.: Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions. J. Immunol. 177(9), 6062-6071 (2006).
7. Kryczek I, Zou L, Rodriguez P et al.: B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 203(4), 871-881 (2006).
8. De Panfilis G, Campanini N, Santini M et al.: Phase-and stage-related proportions of T cells bearing the transcription factor FOXP3 infiltrate primary melanoma. J. Invest. Dermatol. 128(3), 676-684 (2008).
9. high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol. 173(2), 1444-1453 (2004).
10. + regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma. Oncol. Rep. 18(5), 1115-1122 (2007).
11. Collison LW, Workman CJ, Kuo TT et al.: The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450(7169), 566-569 (2007).
12. Kobayashi M, Fitz L, Ryan M et al.: Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170(3), 827-845 (1989).
13. Oppmann B, Lesley R, Blom B et al.: Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13(5), 715-725 (2000).
14. + T cells. Immunity 16(6), 779-790 (2002).
15. Tato CM, Cua DJ: Reconciling ID, EGO, and superego within interleukin-23. Immunol. Rev. 226, 103-111 (2008).
16. Boniface K, Blom B, Liu YJ, De Waal Malefyt R: From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol. Rev. 226, 132-146 (2008).
17. Scheller J, Schuster B, Hölscher C, Yoshimoto T, Rose-John S: No inhibition of IL-27 signaling by soluble gp130. Biochem. Biophys Res. Commun. 326(4), 724-728 (2005).
18. Owaki T, Asakawa M, Morishima N et al.: A role for IL-27 in early regulation of Th1 differentiation. J. Immunol. 175(4), 2191-2200 (2005).
19. Batten M, Li J, Yi S et al.: Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat. Immunol. 7(9), 929-936 (2006).
20. Stumhofer JS, Laurence A, Wilson EH et al.: Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat. Immunol. 7(9), 937-945 (2006).
21. Yoshimoto T, Yoshimoto T, Yasuda K et al.: IL-27 suppresses Th2 cell development and Th2 cytokines production from polarized Th2 cells: a novel therapeutic way for Th2-mediated allergic inflammation. J. Immunol. 179(7), 4415-4423 (2007).
22. Neufert C, Becker C, Wirtz S et al.: IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1. Eur. J. Immunol. 37(7), 1809-1816 (2007).
23. Stumhofer JS, Silver JS, Laurence A et al.: Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat. Immunol. 8(12), 1363-1371 (2007).
24. Fitzgerald DC, Zhang GX, El-Behi M et al.: Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat. Immunol. 8(12), 1372-1379 (2007).
25. Awasthi A, Carrier Y, Peron JP et al.: A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat. Immunol. 8(12), 1380-1389 (2007).
26. Brunda MJ, Luistro L, Warrier RR et al.: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178(4), 1223-1330 (1993). □ First report to demonstrate the anti-tumor activity of IL-12.
27. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J: Inhibition of angiogenesis in vivo by interleukin 12. J. Natl Cancer Inst. 87(8), 581-586 (1995). □ First report to demonstrate the antiangiogenic activity of IL-12.
28. Yang X, Chu Y, Wang Y, Zhang R, Xiong S: Targeted in vivo expression of IFN-γ-inducible protein 10 induces specific antitumor activity. J. Leukoc. Biol. 80(6), 1434-1444 (2006).
29. Atkins MB, Robertson MJ, Gordon M et al.: Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res. 3(3), 409-417 (1997). □ First report of a Phase I clinical trial using human IL-12 in patients with malignancies.
30. Bajetta E, Del Vecchio M, Mortarini R et al.: Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin. Cancer Res. 4(1), 75-85 (1998).
31. Del Vecchio M, Bajetta E, Canova S et al.: Interleukin-12: biological properties and clinical application. Clin. Cancer Res. 13(16), 4677-4685 (2007).
32. Lee P, Wang F, Kuniyoshi J et al.: Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J. Clin. Oncol. 19(18), 3836-3847 (2001).
33. Cebon J, Jäger E, Shackleton MJ et al.: Two Phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immun. 3, 7 (2003).
34. Peterson AC, Harlin H, Gajewski TF: Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J. Clin. Oncol. 21(12), 2342-2348 (2003).
35. Hamid O, Solomon JC, Scotland R et al.: Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin. Cancer Res. 13(1), 215-222 (2007).
36. Triozzi PL, Allen KO, Carlisle RR, Craig M, Lo Buglio AF, Conry RM: Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma. Clin. Cancer Res. 11(11), 4168-4175 (2005).
37. Heinzerling L, Burg G, Dummer R et al.: Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum. Gene Ther. 16(1), 35-48 (2005).
38. Sangro B, Melero I, Qian C, Prieto J: Gene therapy of cancer based on interleukin 12. Curr. Gene Ther. 5(6), 573-581 (2005).
39. Daud AI, De Conti RC, Andrews S et al.: Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J. Clin. Oncol. 26(36), 5896-5903 (2008).
40. Rodriguez-Galan MC, Reynolds D, Correa SG, Iribarren P, Watanabe M, Young HA: Coexpression of IL-18 strongly attenuates IL-12-induced systemic toxicity through a rapid induction of IL-10 without affecting its antitumor capacity. J. Immunol. 183(1), 740-748 (2009).
41. Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH: Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin. Biol. Ther. 7(11), 1705-1721 (2007).
42. Komita H, Zhao X, Katakam AK, Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity. Cancer Gene Ther. 16(12), 883-891 (2009).
43. Lo CH, Lee SC, Wu PY et al.: Antitumor and antimetastatic activity of IL-23. J. Immunol. 171(2), 600-607 (2003). □ First report to demonstrate the anti-tumor activity of IL-23.
44. Oniki S, Nagai H, Horikawa T et al.: Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res. 66(12), 6395-6404 (2006).
45. Wang J, Kobayashi Y, Sato A, Kobayashi E, Murakami T: Synergistic anti-tumor effect by combinatorial gene-gun therapy using IL-23 and IL-18 cDNA. J. Dermatol. Sci. 36(1), 66-68 (2004).
46. Kaiga T, Sato M, Kaneda H, Iwakura Y, Takayama T, Tahara H: Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. J. Immunol. 178(12), 7571-7580 (2007).
47. Overwijk W W, De Visser KE, Tirion FH et al.: Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J. Immunol. 176(9), 5213-5222 (2006).
48. Yuan X, Hu J, Belladonna ML, Black KL, Yu JS: Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma. Cancer Res. 66(5), 2630-2638 (2006).
49. Hu J, Yuan X, Belladonna ML et al.: Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res. 66(17), 8887-8896 (2006).
50. Langowski JL, Zhang X, Wu L et al.: IL-23 promotes tumour incidence and growth. Nature 442(7101), 461-465 (2006).
51. Hisada M, Kamiya S, Fujita K et al.: Potent antitumor activity of interleukin-27. Cancer Res. 64(3), 1152-1156 (2004). □ First report to demonstrate the anti-tumor activity of IL-27.
52. + T cell generation with enhanced granzyme B expression by IL-27. J. Immunol. 175(3), 1686-1693 (2005).
53. Shimizu M, Shimamura M, Owaki T et al.: Antiangiogenic and antitumor activities of IL-27. J. Immunol. 176(12), 7317-7324 (2006).
54. Hu P, Hu HD, Chen M et al.: Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. Mol. Immunol. 46(8-9), 1654-1662 (2009).
55. Liu L, Wang S, Shan B et al.: IL-27-mediated activation of natural killer cells and inflammation produced antitumour effects for human oesophageal carcinoma cells. Scand. J. Immunol. 68(1), 22-29 (2008).
56. Matsui M, Kishida T, Nakano H et al.: Interleukin-27 activates natural killer cells and suppresses NK-resistant head and neck squamous cell carcinoma through inducing antibody-dependent cellular cytotoxicity. Cancer Res. 69(6), 2523-2530 (2009).
57. Shinozaki Y, Wang S, Miyazaki Y et al.: Tumor-specific cytotoxic T cell generation and dendritic cell function are differentially regulated by interleukin 27 during development of anti-tumor immunity. Int. J. Cancer 124(6), 1372-1378 (2009).
58. Dibra D, Cutrera JJ, Xia X, Birkenbach MP, Li S: Expression of WSX1 in tumors sensitizes IL-27 signaling-independent natural killer cell surveillance. Cancer Res. 69(13), 5505-5513 (2009).
59. Yoshimoto T, Morishima N, Mizguchi I et al.: Antiproliferative activity of IL-27 on melanoma. J. Immunol. 180(10), 6527-6535 (2008).